Novartis Q3 Earnings Beats Expectations On Strong Sales From Key Drugs, Lifts 2024 Outlook

On Tuesday, Novartis AG (NYSE:NVS) reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), beating the consensus of $12.76 billion. Volume contributed 12 percentage points to growth.

The Swiss pharma giant reported adjusted EPS of $2.06, up from $1.74 a year ago and beating the consensus of $1.96

Core operating profit for the third quarter grew to $5.15 billion from $4.41 billion the year prior.

Also Read: European Medicines Agency’s Panel Supports Approval Of Novartis’ Kisqali In Patients With Early-Breast Cancer

Novartis generated $6 billion in free cash flow for the third quarter, up 18% year-over-year.

“All ...